Ardelyx, Inc. announced that Onaiza Cadoret-Manier, an industry veteran with deep biopharmaceutical commercial experience, has joined the company's Board effective March 12, 2020, to serve as a Class I director until the company’s 2021 Annual Meeting of Stockholders and until her successor is duly elected and qualified, or until her earlier death, resignation or removal. Ms. Cadoret-Manier replaces Annalisa Jenkins, who stepped down from the board, the Audit Committee of the Board and the Nominating and Governance Committee of the Board effective March 12, 2020 in order to be closer and more involved with her Board responsibilities in Europe. Annalisa Jenkins joined the company's board of directors in 2015. Ms. Cadoret-Manier is an international commercialization and operations executive and life sciences industry veteran with over 30 years of experience driving growth for start-up and Fortune 500 companies. She has led and directed multiple new product launches with responsibility for product planning and commercialization through all phases of the product life cycle and across multiple therapeutic areas to heightened success in highly competitive markets. Ms. Cadoret-Manier currently serves as chief corporate development and commercial officer at Ionis Pharmaceuticals and previously was the chief commercial officer for Grail Biosciences, an early detection genomics company, where she developed the commercial strategy and business model. Prior to Grail, she was vice president of the respiratory franchise at Genentech, where she built and managed a team of more than 400 employees responsible for successfully commercializing medicines that generated approximately $3 billion in revenue. Ms. Cadoret-Manier also has held multiple senior management positions overseeing corporate strategy, alliances, and marketing and sales for numerous disease areas for Genentech, Pfizer and Amylin Pharmaceuticals. Ms. Cadoret-Manier was also appointed to serve as a member of the Nominating and Governance Committee of the Board effective immediately. On March 12, 2020, the company appointed Keith Santorelli as the company's acting principal financial and accounting officer. Mr. Santorelli, age 46, is a Certified Public Accountant with over 25 years of finance and accounting experience. Mr. Santorelli is President and Lead Consultant at Thomas Advisory Partners, LLC.